沃华医药(002107) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 215,317,031.37, representing a decrease of 8.49% compared to CNY 235,281,203.05 in the same period last year[5] - Net profit attributable to shareholders was CNY 9,667,223.23, down 62.01% from CNY 25,449,286.76 year-on-year[5] - The total profit for the period was CNY 10,773,028.68, down 57.33% from CNY 25,245,218.50 year-on-year[8] - The net profit for Q1 2024 was CNY 8,763,449.05, a decrease of 60.6% compared to CNY 22,231,890.00 in Q1 2023[18] - Operating profit for Q1 2024 was CNY 10,652,454.38, a decline of 57.8% compared to CNY 25,228,966.82 in Q1 2023[18] - The total comprehensive income for Q1 2024 was CNY 8,763,449.05, compared to CNY 22,231,890.00 in Q1 2023, reflecting a significant decrease[19] - The company reported a decrease in sales revenue from CNY 274,295,299.10 in Q1 2023 to CNY 254,036,073.89 in Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities increased by 74.60%, reaching CNY 54,487,330.32 compared to CNY 31,206,904.28 in the previous year[5] - Cash flow from operating activities for Q1 2024 was CNY 54,487,330.32, an increase of 74.5% from CNY 31,206,904.28 in Q1 2023[21] - The cash and cash equivalents at the end of Q1 2024 amounted to CNY 453,983,856.82, up from CNY 307,633,936.01 at the end of Q1 2023[21] - Cash and cash equivalents increased to RMB 456,686,925.02 from RMB 401,100,106.17 at the beginning of the quarter, reflecting a growth of 13.8%[13] - The cash outflow from operating activities in Q1 2024 was CNY 199,731,805.75, down from CNY 244,087,278.40 in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,161,752,354.17, a 1.49% increase from CNY 1,144,706,388.58 at the end of the previous year[5] - Total assets as of March 31, 2024, were RMB 1,161,752,354.17, an increase from RMB 1,144,706,388.58 at the beginning of the quarter[16] - Total liabilities increased to RMB 319,510,871.57 from RMB 311,228,355.03, reflecting a rise of 2.1%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,099[10] - The largest shareholder, Beijing Zhongzheng Wanrong Investment Group Co., Ltd., holds 50.27% of the shares[10] Research and Development - Research and development expenses decreased by 45.21%, totaling CNY 8,520,639.75 compared to CNY 15,552,459.72 in the same period last year[8] - Research and development expenses decreased significantly to RMB 8,520,639.75, a reduction of 45.1% compared to RMB 15,552,459.72 in the previous year[17] Earnings Per Share - Basic and diluted earnings per share decreased by 50.00%, both at CNY 0.02 per share[5] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.02, down from CNY 0.04 in Q1 2023[19]